Logo image of NYMX

NYMOX PHARMACEUTICAL CORP (NYMX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NYMX - BSP733981026 - Common Stock

0.2 USD
-0.05 (-19.68%)
Last: 7/6/2023, 8:10:50 PM
0.1767 USD
-0.02 (-11.65%)
After Hours: 7/6/2023, 8:10:50 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NYMX. NYMX was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of NYMX have multiple concerns. NYMX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NYMX had negative earnings in the past year.
In the past year NYMX has reported a negative cash flow from operations.
In the past 5 years NYMX always reported negative net income.
In the past 5 years NYMX always reported negative operating cash flow.
NYMX Yearly Net Income VS EBIT VS OCF VS FCFNYMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

The profitability ratios for NYMX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NYMX Yearly ROA, ROE, ROICNYMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 2K -2K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NYMX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYMX Yearly Profit, Operating, Gross MarginsNYMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -20K -40K -60K -80K -100K

More info and screens

0

2. Health

2.1 Basic Checks

NYMX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NYMX has been reduced compared to a year ago.
NYMX Yearly Shares OutstandingNYMX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
NYMX Yearly Total Debt VS Total AssetsNYMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -504.66, we must say that NYMX is in the distress zone and has some risk of bankruptcy.
NYMX has a Altman-Z score of -504.66. This is amonst the worse of the industry: NYMX underperforms 94.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -504.66
ROIC/WACCN/A
WACCN/A
NYMX Yearly LT Debt VS Equity VS FCFNYMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 0.19 indicates that NYMX may have some problems paying its short term obligations.
NYMX's Current ratio of 0.19 is on the low side compared to the rest of the industry. NYMX is outperformed by 93.55% of its industry peers.
NYMX has a Quick Ratio of 0.19. This is a bad value and indicates that NYMX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.19, NYMX is not doing good in the industry: 93.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
NYMX Yearly Current Assets VS Current LiabilitesNYMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.42% over the past year.
EPS 1Y (TTM)82.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NYMX Yearly Revenue VS EstimatesNYMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 500K 1M 1.5M 2M 2.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NYMX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYMX Price Earnings VS Forward Price EarningsNYMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYMX Per share dataNYMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0.01 -0.01 -0.02 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NYMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYMOX PHARMACEUTICAL CORP

NASDAQ:NYMX (7/6/2023, 8:10:50 PM)

After market: 0.1767 -0.02 (-11.65%)

0.2

-0.05 (-19.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2023-05-12
Earnings (Next)08-15 2023-08-15
Inst Owners0.05%
Inst Owner Change0%
Ins Owners29.39%
Ins Owner Change0%
Market Cap18.10M
Revenue(TTM)N/A
Net Income(TTM)-2.88M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -504.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.09%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y80.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.16%
OCF growth 3YN/A
OCF growth 5YN/A

NYMOX PHARMACEUTICAL CORP / NYMX FAQ

What is the ChartMill fundamental rating of NYMOX PHARMACEUTICAL CORP (NYMX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to NYMX.


Can you provide the valuation status for NYMOX PHARMACEUTICAL CORP?

ChartMill assigns a valuation rating of 0 / 10 to NYMOX PHARMACEUTICAL CORP (NYMX). This can be considered as Overvalued.


What is the profitability of NYMX stock?

NYMOX PHARMACEUTICAL CORP (NYMX) has a profitability rating of 0 / 10.